Telik's TRAP Drug Discovery Technology Surpasses 3 Million Molecular Fingerprint Milestone
News Jul 24, 2008
Telik, Inc. has announced that its library of diverse profiled compounds now exceeds 3.3 million. The expanded library significantly enhances Telik's patented drug discovery technology, Target Related Affinity Profiling (TRAP(R)). TRAP technology exploits the principle that drugs act by adhering to and interacting with key cellular proteins.
Telik has developed a computational approach to determine a molecular fingerprint for each compound in its library. TRAP technology uses these molecular fingerprints to search the library for promising lead molecules and to optimize these structures into new drug candidates.
TRAP also allows the use of a wide range of biologically relevant assays. Several applications of the technology were recently described at the 99th annual meeting of the American Association for Cancer Research.
"This milestone is the latest achievement as we advance Telik's TRAP technology," said Robert Lum, Ph.D., Telik's Vice President of Technology and Preclinical Development. "This library of computational molecular fingerprints, combined with our proprietary data mining algorithms, will help drive the continued growth of Telik's pipeline of preclinical candidates."
TRAP technology has been the focus of several industry partnerships and collaborations with leading academic cancer centers. Telik continues to seek additional TRAP-based partnerships with corporations and academic investigators for the discovery and development of novel therapeutics.
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018